HER2-POSITIVE ADVANCED BREAST CANCER
Clinical trials for HER2-POSITIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Cancer's fuel line in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, colorectal, or lung cancer) that have not responded to standard treatments. The drug works by blocking a key cancer growth signal (PI3Kα:RAS). The main goals are to find a safe …
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 17, 2026 01:46 UTC
-
PET scan could predict best next drug for advanced breast cancer
Disease control Recruiting nowThis study is for people with advanced HER2-positive breast cancer whose disease has worsened after a drug called T-DXd. Researchers will use a special PET scan to see if the cancer still has HER2 on its surface. If the scan is positive, participants get a different drug called T…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for advanced breast cancer: experimental drug combo enters final testing phase
Disease control Recruiting nowThis study tests a new drug called TQB2930 combined with chemotherapy for people with advanced HER2-positive breast cancer who have already tried at least two other anti-HER2 treatments. The goal is to see if TQB2930 works better than the standard drug trastuzumab (Herceptin) plu…
Matched conditions: HER2-POSITIVE ADVANCED BREAST CANCER
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC